EE200100363A - ((Aminoiminometüül)amino)alkaankarboksamiidid ja nende kasutamine ravis - Google Patents

((Aminoiminometüül)amino)alkaankarboksamiidid ja nende kasutamine ravis

Info

Publication number
EE200100363A
EE200100363A EEP200100363A EEP200100363A EE200100363A EE 200100363 A EE200100363 A EE 200100363A EE P200100363 A EEP200100363 A EE P200100363A EE P200100363 A EEP200100363 A EE P200100363A EE 200100363 A EE200100363 A EE 200100363A
Authority
EE
Estonia
Prior art keywords
alkanecarboxamides
aminoiminomethyl
therapy
amino
Prior art date
Application number
EEP200100363A
Other languages
English (en)
Estonian (et)
Inventor
Moinet G�Rard
Cravo Daniel
Mesangeau Didier
Doare Liliane
Kergoat Micheline
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of EE200100363A publication Critical patent/EE200100363A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200100363A 1999-01-11 1999-12-30 ((Aminoiminometüül)amino)alkaankarboksamiidid ja nende kasutamine ravis EE200100363A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9900194A FR2788275B1 (fr) 1999-01-11 1999-01-11 ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique
PCT/EP1999/010468 WO2000042001A1 (en) 1999-01-11 1999-12-30 ((aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy

Publications (1)

Publication Number Publication Date
EE200100363A true EE200100363A (et) 2002-10-15

Family

ID=9540749

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100363A EE200100363A (et) 1999-01-11 1999-12-30 ((Aminoiminometüül)amino)alkaankarboksamiidid ja nende kasutamine ravis

Country Status (27)

Country Link
US (1) US6518458B1 (de)
EP (1) EP1140803B1 (de)
JP (1) JP4567889B2 (de)
KR (1) KR100630291B1 (de)
CN (1) CN1182109C (de)
AR (1) AR022221A1 (de)
AT (1) ATE252553T1 (de)
AU (1) AU760147B2 (de)
BR (1) BR9916858A (de)
CA (1) CA2359454C (de)
CZ (1) CZ20012482A3 (de)
DE (1) DE69912315T2 (de)
DK (1) DK1140803T3 (de)
EE (1) EE200100363A (de)
ES (1) ES2207325T3 (de)
FR (1) FR2788275B1 (de)
HK (1) HK1041689B (de)
HU (1) HUP0200023A3 (de)
ID (1) ID29586A (de)
IL (1) IL144225A0 (de)
NO (1) NO20013420D0 (de)
NZ (1) NZ513467A (de)
PT (1) PT1140803E (de)
RU (1) RU2236401C2 (de)
SK (1) SK285130B6 (de)
WO (1) WO2000042001A1 (de)
ZA (1) ZA200106606B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069782A2 (en) 2004-12-27 2006-07-06 Silence Therapeutics Ag. Lipid complexes coated with peg and their use
MXPA06012722A (es) 2004-05-05 2007-02-14 Atugen Ag Lipidos, complejos de lipido y su uso.
TW200808705A (en) * 2006-06-15 2008-02-16 Sanofi Aventis Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics
KR101670085B1 (ko) * 2006-07-21 2016-10-28 사일런스 테라퓨틱스 게엠베하 단백질 키나아제 3의 발현을 억제하기 위한 수단
WO2010074591A1 (ru) * 2008-12-24 2010-07-01 Закрытое Акционерное Общество "Beptekc" Амиды креатина, способ их получения, средство, обладающее нейропротекторным действием

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153424A (en) * 1965-04-15 1969-05-29 Horlicks Ltd Pharmaceutical Compositions
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
JPH0841008A (ja) * 1994-07-29 1996-02-13 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
CA2217550A1 (en) * 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
RU2125458C1 (ru) * 1997-04-02 1999-01-27 Санкт-Петербургская Государственная Химико-Фармацевтическая Академия Способ получения комплекса, обладающего адаптогенным, гипогликемическим, антигипоксическим и противовоспалительным действием
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
DE19748697A1 (de) * 1997-11-04 1999-05-06 Basf Ag Verfahren zur Herstellung von substituierten Guanidinderivaten

Also Published As

Publication number Publication date
CA2359454A1 (en) 2000-07-20
RU2236401C2 (ru) 2004-09-20
IL144225A0 (en) 2002-05-23
FR2788275A1 (fr) 2000-07-13
JP4567889B2 (ja) 2010-10-20
WO2000042001A1 (en) 2000-07-20
HK1041689B (zh) 2005-09-02
HK1041689A1 (en) 2002-07-19
DE69912315D1 (de) 2003-11-27
DK1140803T3 (da) 2003-12-22
KR100630291B1 (ko) 2006-09-29
ID29586A (id) 2001-09-06
HUP0200023A2 (hu) 2002-05-29
NO20013420L (no) 2001-07-10
CN1182109C (zh) 2004-12-29
JP2002534496A (ja) 2002-10-15
US6518458B1 (en) 2003-02-11
ZA200106606B (en) 2002-11-11
AU3044300A (en) 2000-08-01
EP1140803B1 (de) 2003-10-22
NO20013420D0 (no) 2001-07-10
NZ513467A (en) 2003-08-29
HUP0200023A3 (en) 2003-04-28
ES2207325T3 (es) 2004-05-16
AR022221A1 (es) 2002-09-04
EP1140803A1 (de) 2001-10-10
CN1333747A (zh) 2002-01-30
DE69912315T2 (de) 2004-08-05
FR2788275B1 (fr) 2002-06-14
ATE252553T1 (de) 2003-11-15
CA2359454C (en) 2009-10-27
AU760147B2 (en) 2003-05-08
CZ20012482A3 (cs) 2001-10-17
PT1140803E (pt) 2004-03-31
BR9916858A (pt) 2001-12-04
SK9842001A3 (en) 2001-12-03
SK285130B6 (sk) 2006-07-07
KR20010089822A (ko) 2001-10-08

Similar Documents

Publication Publication Date Title
IL156565A0 (en) N-(phenylsulphonyl) glycine derivatives and their therapeutic use
EE05210B1 (et) Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
NO992373D0 (no) Forlenget anestesi i ledd og kroppshulrom
DK1354888T3 (da) Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter
IS6411A (is) Kaspasa tálmar og notkun þeirra
EE200200414A (et) Dihüdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE04566B1 (et) Epotilooni derivaadid ja nende kasutamine meditsiinis
NO20012245D0 (no) Anthranilsyreamider og anvendelse derav som medikamenter
EE200100568A (et) 6-alkenüül-, 6-alkünüül- ja 6-epoksüepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
EE05067B1 (et) Aminoproplfosfiinhapped ning nende kasutamine meditsiinis
NO975513D0 (no) 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel
FI944600A0 (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
EE200100416A (et) Hargneva ahelaga aminohappe-sõltuvad aminotransferaasinhibiitorid ja nende kasutamine diabeetilise retinopaatia ravis
EE9700288A (et) Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
NO20012738D0 (no) Terapeutiske produkter og anvendelse derav
NO990300L (no) <Alfa>-aminosyreamider, fremstilling og terapeutisk anvendelse derav
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
EE200100363A (et) ((Aminoiminometüül)amino)alkaankarboksamiidid ja nende kasutamine ravis
EE9900135A (et) N-(2-bensotiasolüül)-1-piperidiinetaanamiini derivaadid, nende valmistamine ja kasutamine raviks
EE200300454A (et) Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine